BTIG analyst Ryan Zimmerman raised the firm's price target on Avita Medical to $41 from $8 and keeps a Buy rating on the shares. The analyst notes that his investor call with a UMass Medical School associate professor in the Dermatology department suggests that his prior estimate of addressable vitiligo patient market could prove to be "conservative", also stating that RECELL opportunity may be materially higher. Zimmerman adds that his higher price target on Avita also reflects the impact of Avita's recent redomiciliation on its share count.Read more at:https://thefly.com/landingPageNews.php?id=3122784
AVH on NASDAQ, page-218
Add AVH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$3.53 |
Change
0.030(0.86%) |
Mkt cap ! $246.6M | |||
| Open | High | Low | Value | Volume |
| $3.62 | $3.64 | $3.46 | $1.133M | 322.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 5285 | $3.50 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $3.60 | 1212 | 2 |
View Market Depth
| Last trade - 16.10pm 11/11/2024 (20 minute delay) ? |
| AVH (ASX) Chart |